Sign inJoin waitlistJoin the waitlist

Arthur Winer

Physician · Inova Health System

Credentials: · · · · · ·

History

Inova Health System
2020–Present

Fox Chase Cancer Center
2020–2022
Hematology and Medical Oncology
Temple University Hospital
2017–2020
Internal Medicine
NYU Grossman School of Medicine
2013–2014
New York University Grossman School of Medicine
2009–2013

Research

Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Review · Molecular Cancer Therapeutics · 2018 · First of 3 authors · Corresponding · 529 citations
Identifying and managing the adverse effects of immune checkpoint blockade
Review · Journal of Thoracic Disease · 2018 · First of 3 authors · 71 citations
Dual Checkpoint Inhibition with Ipilimumab plus Nivolumab After Progression on Sequential PD-1/PDL-1 Inhibitors Pembrolizumab and Atezolizumab in a Patient with Lynch Syndrome,…
Case report · The Oncologist · 2019 · First of 8 authors · 34 citations

TC
Timothy Cannon
5 papers
ED
Efrat Dotan
4 papers
Raymond Wadlow
4 papers
Wafik El-Deiry
4 papers
Sylvia Adams
3 papers
AB
Ashish Bains
2 papers
Fern Anari
2 papers · 2 as a fellow
GW
Grant Williams
2 papers
Maxwell Janosky
2 papers · 1 as a fellow
Namrata Vijayvergia
2 papers
Nicole Bubes
2 papers
Pooja Ghatalia
2 papers · 2 as a fellow

Clinical trials

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Principal investigator · Recruiting · Phase 2
Inova Health Care Services
2025–2028
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Principal investigator · Recruiting · Phase 2
Inova Health Care Services
2024–2028
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
Principal investigator · Recruiting · Phase 2, Phase 3
Inova Health Care Services
2023–2029
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2028